Last updated: February 20, 2026
What is the scope of AU2020233746?
Patent AU2020233746 is titled "Method for treating or preventing COVID-19 using monoclonal antibodies," filed by Singlomics International Pte Ltd. Its primary focus is on a specific method of administering monoclonal antibodies (mAbs) to treat or prevent COVID-19. The patent’s scope encompasses the composition, dosage, administration method, and specific monoclonal antibodies designed for COVID-19 therapy.
The patent claims protect a class of monoclonal antibodies with defined binding regions targeting the SARS-CoV-2 virus, particularly the spike (S) protein. It emphasizes the therapeutic use of these antibodies, especially in human subjects. The patent also includes claims covering the antibody formulations and their uses in prophylaxis and treatment of COVID-19.
The patent's scope covers both the antibody molecules and their application protocols, focusing on specific epitopes on the spike protein. It appears to restrict claims to particular antibody sequences and their methods of production, delivery, and use in COVID-19 related indications.
What are the key claims and their implications?
Main Claims Overview
-
Monoclonal Antibodies Specific to SARS-CoV-2: The patent claims monoclonal antibodies that target a specific epitope on the spike protein, notably regions involved in receptor binding, conferring neutralizing activity.
-
Binding Specificity and Affinity: Claims specify antibodies with high binding affinity (e.g., KD in nanomolar range) to the viral spike protein, including dominant circulating variants.
-
Use in Prevention and Treatment: Claims extend to methods of using the antibodies for prophylactic and therapeutic purposes, explicitly covering administration timing, dosage, and routes.
-
Formulations: Claims include antibody formulations with carriers, stabilizers, or adjuvants suitable for human administration.
-
Manufacturing and Delivery: Claims describe processes of producing these monoclonal antibodies, potentially including recombinant expression systems and purification methods.
-
Variants and Mutations: Some claims cover antibodies capable of binding to multiple SARS-CoV-2 variants, including Alpha, Beta, Delta, and Omicron.
Implications
- The claims are narrowly focused on specific monoclonal antibodies targeting key epitopes on the spike protein, emphasizing therapeutic use.
- They exclude broad classes of antibodies that do not meet the specified binding and efficacy parameters.
- The patent aims to cover the anti-SARS-CoV-2 antibody molecules, their formulations, and methods of application.
Limitations & Potential Challenges
- Patent scope relies heavily on the antibody sequences and binding characteristics defined in the claims.
- Variations in SARS-CoV-2 mutations may affect the scope’s relevance for future circulating variants.
- The claims do not explicitly cover bispecific or multispecific antibodies, limiting coverage to the specified monoclonal antibodies.
What is the current patent landscape for COVID-19 monoclonal antibodies in Australia?
Major Patent Holders
- Regeneron Pharmaceuticals: Holds patents related to their antibody cocktail REGN-COV2.
- Eli Lilly: Owns patents on bamlanivimab and etesevimab.
- AstraZeneca: Has patents on their monoclonal antibodies such as AZD7442.
- Singlomics: The applicant for AU2020233746, aiming to secure rights specific to their antibodies.
Patent Families in Australia
- The patent family includes filings across jurisdictions such as the US, Europe, and China, with corresponding patent applications.
- AU2020233746 is a national phase application, likely claiming priority from earlier international applications.
Competitive Positioning
- The patent filings indicate a competitive field where multiple companies seek protection for similar antibody classes.
- Patent validity is subject to prior art challenges, particularly for antibodies developed early in the pandemic.
Patent Grant Status and Term
- As of the latest update, AU2020233746 is pending examination.
- The patent, once granted, would typically last 20 years from the filing date, expected around 2034, assuming patent term adjustments.
Key Patent Citings and Critical Overlaps
- Similar COVID-19 antibody patents cite sequences and methods comparable to AU2020233746.
- Overlap exists with existing patents on spike protein epitopes, which may influence scope interpretation during examination.
Summary of Market and Patent Dynamics
| Aspect |
Detail |
| Patent applicant |
Singlomics International Pte Ltd |
| Filing date |
December 14, 2020 |
| Priority date |
December 14, 2020 |
| Application status |
Pending |
| Patent family |
Includes US, Europe, China filings |
| Key protected features |
Antibody sequences targeting SARS-CoV-2 spike epitope, methods of use, formulations |
| Key competitors |
Regeneron, Eli Lilly, AstraZeneca, other biotech firms |
Key Takeaways
- AU2020233746 primarily protects specific monoclonal antibodies targeting SARS-CoV-2, with a focus on formulation, application, and manufacturing.
- The scope is narrow, tied to particular sequences and epitopes, and includes methods of prophylaxis and treatment.
- The Australian patent landscape is competitive, with multiple filings related to COVID-19 antibodies, potentially overlapping with this patent.
- Patent validity may be challenged based on prior art, especially as many similar patents emerge globally.
- The patent's enforceability and commercial value depend on clinical efficacy, variant coverage, and regulatory approvals.
Frequently Asked Questions
1. How does AU2020233746 compare to other COVID-19 antibody patents?
It focuses on specific monoclonal antibodies with claims on binding epitopes on the spike protein, rather than broad antibody classes or mechanisms. Many other patents cover antibody cocktails, but this one emphasizes certain sequences and formulations.
2. When could AU2020233746 be granted, and how long would protection last?
If approved, it could be granted within 1-2 years of examination start, with patent life lasting until approximately 2040. Patent term adjustment could extend protection.
3. What are the main challenges to the patent's scope validity?
Prior art patents describing similar spike protein epitopes, antibody sequences, or treatment methods could challenge its novelty or inventive step.
4. Does the patent cover variants like Omicron?
Claims include antibodies binding multiple variants, with some coverage explicitly mentioning Omicron, depending on the binding data provided during prosecution.
5. How can competitors circumvent this patent?
Developing antibodies targeting different epitopes, using alternative formulations, or designing bispecific antibodies could avoid infringement.
[1] World Intellectual Property Organization. (2022). Patent Landscape Report on COVID-19 Therapeutics.
